Skip to content

A clinical study to see the effect of some Ayurvedic formulations in the management of Mental Retardation.

Clinical Evaluation of Sarasvata Ghrita in the Management of Cognitive Deficit.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/09/005017
Enrollment
45
Registered
2014-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- COGNITIVE DEFICIT

Interventions

Intervention1: SARASWATA GHRITA: Dose 6 gms. Dosageform: Ghrita (Ghee) Route of Administration : Oral Time of Administration: Twice a day
before food. Packing form:400 gms. pet jar Anupana :Ushnodaka(Warm water) Duration of therapy: 3 months Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

Central Council for Research in Ayurvedic Sciences CCRAS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children of either sex aged in between 8 to 13 years. 2. Children with Intelligence Quotient 63 - 80 as per Binet Kamat Test (BKT). 3. Willing and able to participate for 3 months (consent to be obtained from Parent(s) / Guardian(s)/ Assent from children wherever possible).

Exclusion criteria

Exclusion criteria: 1. Children with severe infection and/or clinically significant hepatic, respiratory, renal, cardiac or hematological disorders. 2. Children with abnormal laboratory values at admission in to the study: serum creatinine > 1.2 mg/dl, SGOT, SGPT > 3times upper limit of normal; serum Bilirubin or Alkaline phosphatase >1.5 times upper limit of normal. 3. Patientâ??s guardian who cannot be relied upon to comply with the test procedures or are unwilling to give informed consent. 4. The Children had any intramuscular, intra-articular or intravenous carticosteroids within 4 weeks prior to study entry. 5. The Children with a history of recent and clinically significant drug abuse. 6. The Children with pre-existing blood dyscrasias, eg., bone marrow hypoplasia, leukopenia, thrombocytopenia etc. 7. The Children is unlikely to comply with protocol, eg., un cooperative attitude, inability to return for follow-up visits, and unlikelihood of complete study. 8. Children in whom another investigational drug was used within 3 months prior to entry in this study. 9. Children with poorly controlled epilepsy (H/o attack in last 3 months). 10. Children with a history of head injury. 11. Children to whom BKT canâ??t be administered for any reason.

Design outcomes

Primary

MeasureTime frame
Changes in BKTTimepoint: Changes in BKT AT THE TIME OF RECRUITMENT AND AT THE END THE STUDY PERIOD THAT IS AFTER 90 DAYS WILL BE ASSESSED.

Secondary

MeasureTime frame
Change in Modified Child Mini Mental Scale Examination MMSE Abnormal behavioral test Parental Perception Evaluation Timepoint: MMSE AND ABC AT BASELINE AND AT THE END OF 30 60 90 DAYS PARENTAL PERCEPTION EVALUATION AT THE END OF 90 DAYS

Countries

India

Contacts

Public ContactDR D SUDHAKAR

ACAMHNS

ACAMHNS.BENGALURU@GMAIL.COM08026995243

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026